Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Has Average Price Target of $6.75 According to Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.50.

ZNTL has been the subject of several recent research reports. Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target for the company. Leerink Partners began coverage on Zentalis Pharmaceuticals in a research report on Monday, October 5th. They set an “outperform” rating and a $8.00 price objective on the stock. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 30th. They issued an “equal weight” rating and a $5.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd.

Insider Activity at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters purchased 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the transaction, the insider owned 17,844,973 shares in the company, valued at $62,457,405.50. The trade was a 32.09% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $27,000. CTC Alternative Strategies Ltd. purchased a new position in Zentalis Pharmaceuticals during the first quarter worth about $29,000. Spark Investment Management LLC purchased a new position in Zentalis Pharmaceuticals during the second quarter worth about $61,000. State of Wyoming acquired a new position in Zentalis Pharmaceuticals in the 1st quarter valued at about $67,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $69,000.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock opened at $2.64 on Monday. The company has a market cap of $189.21 million, a price-to-earnings ratio of -1.35 and a beta of 1.93. Zentalis Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $6.95. The firm has a 50-day moving average of $3.54 and a two-hundred day moving average of $3.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.